Table 1—

Functional status, haemodynamics and magnetic resonance imaging measurements at baseline and follow-up

BaselineFollow-up
Functional status
 NYHA II:III:IV5:22:313:15:2
 6-MWD m425 (342–509)461 (370–591)
Haemodynamics
 Pra mmHg6 (4–10)6 (3–10)
 Prv syst mmHg72 (56–93)65 (56– 82)*
 Prv diast mmHg9 (5–13)9 (6–13)
 mPAP mmHg47 (38–57)43 (32–52)*
SV,O2 %67 (58–71)66 (61–74)
 CI L·min-1·m22.8 (2.0–3.6)3.1 (2.6–4.0)
 PVRI dynes·s·cm-5·m-2384 (236–528)324 (160–430)*
 Ppcw mmHg6 (5–9)7 (5–11)
MRI measurements
 RVEDVI ml·m-292 (76–111)98 (76–109)
 RVMI g·m-238 (29–51)45 (31–53)
 RVEF %34 (23–50)38 (31–53)
NT-proBNP pg·mL-1333 (192–1363)541 (99–1027)
  • Data are presented as n or median (interquartile range). NYHA: New York heart association; 6-MWD: 6-min walk distance; Pra: right atrial pressure; Prv: right ventricular pressure; syst: systolic; diast: diastolic; mPAP: mean pulmonary arterial pressure; SV,O2: mixed venous oxygen saturation; CI: cardiac index; PVRI: pulmonary vascular resistance index; Ppcw: pulmonary capillary wedge pressure; RVEDVI: right ventricular end-diastolic volume index; RVMI: right ventricular mass index; RVEF: right ventricular ejection fraction; NT-proBNP: N-terminal pro brain natriuretic peptide. *: p<0.05, between baseline and follow-up.